Last updated: April 23, 2026
What Does CN101420854 Cover, and How Broad Are Its Claims in China’s Patent Landscape?
CN101420854 is a Chinese patent publication that discloses a specific pharmaceutical composition and/or method claim set (as typically drafted for China drug patents). Without the claim text and bibliographic details (applicant, title, publication dates, and claim list), a complete and accurate scope-and-claims analysis and a landscape mapping of related filings cannot be produced to a standard suitable for decision-making.
CN101420854 cannot be analyzed in full scope and claim detail from the information provided in this prompt. The request requires exact claim language, claim dependencies, defined terms, and cited prior art/related family members. Those elements are not present here, so any attempt to fill gaps would risk factual errors.
What Claims Exist in CN101420854?
A claim-by-claim scope analysis requires the patent’s exact claim set, including:
- independent claim(s) (composition, dosage form, method of treatment, manufacturing method, or use claims)
- dependent claims (active ingredient specificity, excipient lists, process steps, particle size, stability parameters, polymorph form, route restrictions)
- any Markush language, ranges (e.g., concentration, pH, temperature, time), and defined ranges
- whether the claims are product, process, or Swiss-type/use format
- claim numbering and whether there are claim amendments across publication/grant
This cannot be extracted from the prompt.
What Is the Patent Scope in Practical Commercial Terms?
To translate CN101420854 scope into actionable commercial impact, the analysis must map:
- which active pharmaceutical ingredients (APIs) are covered
- whether the claims cover:
- the API per se
- a salt/solvate/polymorph of the API
- a formulation with specific excipients
- a dosing regimen (dose, frequency, duration)
- a method of manufacture with defined parameters
- the level of claim specificity (broad genus vs narrow embodiment)
- whether design-around exists via:
- alternative salts/polymorphs
- alternate excipient systems
- alternate processes
None of the above is available from the prompt.
How Does CN101420854 Fit the Wider China Drug Patent Landscape?
A landscape requires at minimum:
-
Family linkage
- priority date(s)
- PCT/overseas filing equivalents
- continuation/divisional equivalents (if any)
-
China prosecution status
- whether CN101420854 is granted or lapsed
- term adjustments and current legal status
- effective term end date in China (for enforcement window)
-
Forward and backward citation network
- cited documents in the patent
- later publications that reference the same technical core
-
Competitor and generic exposure
- likely generic development targets
- whether later filings attempt to carve out claim features
These elements require access to the patent record and claim text.
What Enforcement-Relevant Features Must Be Checked?
For China drug patents, enforcement hinges on claim construction and evidence. The scope analysis typically checks:
- product claim elements: ingredient identity, form, and formulation parameters
- method claim elements: step order, conditions, and process parameters
- infringement proof: composition analysis, manufacturing records, and test data
- validity risk: obviousness-type reasoning under CN practice, enablement, and support for broad ranges
- whether the claims are susceptible to narrowing during prosecution or in reexamination
Again, the content of CN101420854 is not available here.
What Can Be Done Reliably With the Provided Information?
Nothing actionable can be stated about scope and claims, because the prompt does not include:
- patent title
- abstract
- full claim text
- applicant/assignee
- publication dates and grant status
- independent/dependent claim structure
- cited art and related documents
Under the requirement for “complete and accurate response,” that missing record prevents a correct analysis.
Key Takeaways
- CN101420854’s scope and claims cannot be analyzed from the prompt alone.
- A valid landscape assessment requires the patent’s bibliographic record, exact claim language, and legal status details.
- Any attempt to describe coverage or claim breadth without the claim set would not meet the accuracy standard required for patent and litigation decision-making.
FAQs
1) Can CN101420854 be assessed for claim breadth without the exact claim text?
No. Claim breadth depends on the precise independent and dependent claim language, ranges, and defined terms.
2) Does a Chinese publication number alone identify the drug product or composition covered?
No. Bibliographic and claim-level data are required to map the patent to an API, formulation, or method.
3) Can the patent landscape be mapped without family and status data?
No. Landscape work requires priority and family members, prosecution and grant status, and citation networks.
4) What matters most for infringement in China drug patents?
The claim elements (including formulation or process conditions) and the ability to prove those elements in the accused product or process.
5) What is typically the fastest path to a usable landscape for a CN drug patent?
Extract title, abstract, and full claim set, then pull legal status, family equivalents, citations, and later competing filings.
References (APA)
[1] No sources were provided or retrievable from the prompt content.
